$54.99
Research Studies:
FREE Shipping on
orders over $200
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. The products offered on this website are intended solely for research and laboratory use. These products are not intended for human or animal consumption. They are not medicines or drugs and have not been evaluated or approved by the FDA to diagnose, treat, cure, or prevent any disease or medical condition. Any form of bodily introduction is strictly prohibited by law.
Prostamax 20mg is a research-use-only laboratory material supplied for controlled research workflows, compound characterization, and analytical documentation review. It is manufactured under rigorous quality standards to support consistency, traceability, and batch-specific verification for qualified laboratory settings.
Prostamax 20mg is intended strictly for laboratory research use only. This product is not intended for human or animal consumption, therapeutic use, diagnostic use, clinical use, veterinary use, or as a food, drug, cosmetic, dietary supplement, or household product.
| CAS No. | Coming Soon |
|---|---|
| Molecular Formula | Coming Soon |
| Molecular Weight | Coming Soon |
| Purity | ≥99% |
| Sequence | Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe |
| Applications | Prostate function studies, hormonal regulation research, urinary health investigation |
| Synthesis Method | Solid-phase synthesis |
| Format | Lyophilized powder |
| Solubility | Water/Sterile Diluent |
| Stability & Storage | Up to 24 months at -20°C. Avoid repeated freeze-thaw cycles. |
| Appearance | White to off-white powder |
| Regulatory/Compliance | Not for human consumption. For research use only. |
| Safety Information | MSDS available upon request |
Consider these supplementary peptides for a comprehensive research approach.
Researchers evaluating where to buy Prostamax for research should begin with compound identity, batch documentation, and RUO labeling rather than consumer-facing claims. Prostamax is cataloged as the KEDP tetrapeptide, with the sequence H-Lys-Glu-Asp-Pro-OH and molecular formula C20H33N5O9 in PubChem [1]. This product-page guide frames Prostamax peptide documentation for laboratory research, COA review, analytical testing, and literature interpretation only.
Researchers evaluating where to buy Prostamax for research should first check the compound identity, batch-specific COA, analytical testing method, lot number, label consistency, and RUO documentation. Products discussed in this article are intended for laboratory research use only and are not intended for human or animal consumption. Scientific literature should be treated as background context, not product-use guidance.
The keyword “buy Prostamax” becomes RUO-safe only when the intent is reframed as “buy Prostamax for research.” That wording keeps the page focused on research procurement, documentation review, and laboratory material evaluation.
For technical procurement teams, the commercial question is not a consumer question. It is whether the product listing, COA, analytical data, lot record, and label tell the same story.
The first documents to review are the product listing, batch-specific certificate of analysis, analytical method summary, and lot-level records. A COA should connect to a specific batch and should not be treated as a generic marketing asset.
For reference materials, NIST describes certified reference material documentation as including certified values, uncertainty, and traceability statements [28]. Research peptide COA review should use the same general discipline: identify what was tested, by whom, when, and for which lot.
RUO labeling matters because it defines the intended research context for the material. FDA guidance for research-use-only IVD products emphasizes that RUO labeling must be consistent with the intended research context and not represented for diagnostic purposes [22].
Although Prostamax peptide product pages are not IVD pages, the labeling principle is useful for editorial discipline: the product page should not drift into clinical-use language, product-performance language, or consumer outcomes.
A Prostamax peptide product page should serve qualified researchers, laboratory buyers, and technical procurement teams. The purpose is to help them evaluate compound identity, documentation quality, and research literature boundaries.
This is not a wellness article, clinical guide, or consumer buying guide. It is a product-page research guide for evaluating RUO peptide documentation.
RUO positioning requires clear separation between literature context and product claims. FDA’s in vitro diagnostic labeling regulation includes language for products in the laboratory research phase, including the statement “For Research Use Only. Not for use in diagnostic procedures” [23].
That principle supports a careful product-page framework. A Prostamax research page should emphasize documentation, not outcomes.
Laboratory research use shapes product copy by limiting the page to compound identity, testing, storage records, and literature context. The copy should not translate study findings into claims about a Pure Lab Peptides material.
A safer product-page sentence says: “Published literature has examined KEDP in chromatin-related research models.” It should not say that a product produces a biological outcome.
Prostamax is a synthetic tetrapeptide research compound associated with the KEDP sequence. PubChem lists Prostamax as H-Lys-Glu-Asp-Pro-OH, sequence KEDP, molecular formula C20H33N5O9, and molecular weight 487.51 g/mol [1].
The prostamax peptide description should stay technical. It can discuss sequence, compound identity, peptide class, and research literature, but it should not create a product-use claim.
Prostamax fits a short peptide research lane because KEDP contains four amino acid residues: lysine, glutamic acid, aspartic acid, and proline [1]. Short peptide literature often discusses peptide-DNA interactions, chromatin context, and gene expression models as research categories [5].
For Pure Lab Peptides, the key classification is simple: Prostamax is a research peptide, and its product-page content should remain tied to RUO documentation.
Peptide sequence matters because identity review depends on matching the named compound to its expected amino acid order. PubChem provides the KEDP sequence for Prostamax [1].
Sequence review also helps researchers compare product-page information against COA data, LC-MS output, and supplier documentation. If the sequence, name, and mass information do not align, procurement review should pause.
A synthetic tetrapeptide description is useful when it is precise, documentable, and testable. General peptide synthesis literature describes solid-phase peptide synthesis as a standard method family for constructing peptides [26].
Useful product-page copy should therefore describe Prostamax with verifiable identity terms: KEDP, H-Lys-Glu-Asp-Pro-OH, molecular formula, molecular weight, COA, HPLC, LC-MS, and batch traceability.
A Prostamax product page should answer commercial research intent without becoming a consumer guide. The safest conversion path is documentation-first.
That means the article can help research buyers understand what to review before selecting a lab peptide. It should not imply product outcomes.
The phrase “buy Prostamax for research” fits technical procurement when it points to documentation review. It should guide laboratory buyers toward COA availability, purity data, identity confirmation, label consistency, and lot traceability.
That is the difference between commercial research intent and unsafe consumer intent. One evaluates records. The other seeks personal outcomes.
Product documentation supports research material review by making the material auditable. The product listing should align with COA data, lot number, test date, supplier records, and storage notes.
For measurement systems, ISO/IEC 17025 is widely used to demonstrate testing-laboratory competence and valid results [21]. Research buyers can use that standard as a high-level benchmark when evaluating third-party testing language.
Bioregulator peptide research often examines short peptides in molecular, cellular, DNA, chromatin, and gene-expression contexts. A systematic review by Khavinson and colleagues discusses short peptides, DNA interactions, histone-related mechanisms, gene expression, and protein synthesis as research themes [5].
That literature does not create a product claim for Prostamax. It provides a background map for interpreting Prostamax research in a careful RUO frame.
The prostate is a gland in the male reproductive system, and NCI describes it as surrounding part of the urethra below the bladder [11]. Anatomy literature describes prostate tissue as organized into epithelial and stromal compartments, which are relevant to cell and tissue research models [12].
For Prostamax research, prostate tissue context should remain anatomical and model-based. Phrases such as prostate health belong in claim-boundary review, not product positioning.
Cellular model selection shapes what a study can and cannot show. Prostate epithelial-stromal co-culture research illustrates how model design can influence tissue-context interpretation [13].
For a Prostamax product page, this means literature should be filtered by model type. In vitro findings, preclinical literature, and analytical documentation are not interchangeable.
Chromatin is the DNA-protein structure that packages genetic material in eukaryotic cells. NCBI Bookshelf describes heterochromatin as a highly condensed chromatin state that is generally transcriptionally inactive [9].
This background helps explain why Prostamax literature often uses chromatin and heterochromatin terminology. It should still be framed as research interpretation, not as a product claim.
Chromatin structure appears in the literature as a way to study DNA accessibility, gene regulation, and nuclear organization. Review literature describes chromatin compaction as relevant to transcription, replication, and DNA repair processes [10].
One Prostamax paper examined the peptide bioregulator Prostamax on heterochromatin of lymphocytes in situ and reported thermal changes interpreted as small structural changes in chromatin [2]. That is a model-specific finding, not product-page positioning.
Heterochromatin is an architectural feature of eukaryotic chromosomes with specific functional roles in genome organization [8]. In product-page copy, heterochromatin should be used as a literature term, not a promised endpoint.
A second KEDP-related paper discussed chromatin deheterochromatinization in an age-related research context and reported changes in chromosomal parameters, including sister chromatid exchanges [3]. That evidence remains model-specific.
Lymphocyte chromatin literature can be relevant to peptide bioregulator research because it provides a cellular model for chromatin state observations. Khavinson, Lezhava, and Malinin examined short peptides on lymphocyte chromatin in senile subjects in a published study [4].
The careful phrasing matters. The product page can describe “lymphocyte chromatin literature,” but it should not turn that literature into a claim about the product.
Published Prostamax research is narrow compared with broader peptide literature. The most relevant sources are compound identity records, chromatin model studies, short peptide reviews, and analytical chemistry guidance.
Some published literature outside the scope of RUO product use has examined this compound class in human study settings. That literature should not be interpreted as a use claim for research-use-only materials.
Source quality determines how much weight a research buyer should place on a claim. Peer-reviewed literature, official databases, and official standards should rank above marketing pages, forums, and unsourced summaries.
For Prostamax, PubChem supports compound identity [1]. PubMed-indexed Prostamax literature supports chromatin-context review [2] [3]. Analytical standards and method-validation guidance support documentation review [14].
Published data can support careful statements about what a study examined. It cannot support claims about Pure Lab Peptides materials unless the exact product lot was tested in the relevant study.
A Prostamax paper can be summarized as a chromatin-model report [2]. A KEDP paper can be summarized as an age-related chromatin-model report [3]. Neither should be turned into a product-performance statement.
Research buyers need a way to sort literature without overstating it. A simple evidence ladder helps: official database identity, analytical testing, model-specific literature, broader peptide reviews, and RUO boundary review.
| Research Area | What Literature Examines | Evidence Type | RUO Interpretation |
|---|---|---|---|
| Compound identity | PubChem lists Prostamax as KEDP with molecular formula and molecular weight [1] | Official database | Supports identity review, not product claims |
| Chromatin literature | Prostamax and KEDP papers examine heterochromatin and chromosomal parameters [2] [3] | Published research | Supports literature context only |
| Short peptide mechanisms | Reviews discuss short peptide interaction with DNA, histone proteins, and gene expression models [5] [6] | Review and modeling literature | Supports same-lane background |
| Analytical verification | HPLC and LC-MS are used in peptide analysis and impurity characterization [16] [17] | Analytical chemistry | Supports documentation review |
| RUO positioning | FDA RUO guidance separates research labeling from diagnostic positioning [22] | Official guidance | Supports claim-boundary discipline |
An evidence ladder helps prevent overstatement. In vitro research can describe model observations; model-based literature can describe experimental endpoints; official databases can describe identity; analytical records can describe a batch.
Short peptide modeling literature proposes DNA-peptide interaction frameworks for multiple short peptides [6]. That is useful background, but it should remain separate from a product-page claim.
Literature summaries remain RUO-safe when they use neutral verbs: examined, reported, modeled, characterized, or investigated. They become unsafe when they imply that a product delivers an outcome.
Phrases tied to product performance or consumer outcomes require controlled framing because they can become product claims if separated from model-specific literature context.
The key research boundary is simple. Literature can describe what a study examined; a product page cannot claim that the listed material creates the same result.
This is especially important for boundary-sensitive terms such as prostate health or prostatitis. Those terms may appear in literature or search behavior, but they should not define RUO product positioning.
Claim boundaries matter because RUO copy should not imply clinical-use language, therapeutic-use language, or consumer-facing outcomes. FDA RUO guidance emphasizes intended-use consistency in labeling and distribution context [22].
For Prostamax, claim boundaries keep the article focused on compound identity, COA review, analytical testing, lot traceability, and literature limits.
Product-page copy should not become a disease guide, personal-use guide, wellness guide, or clinical article. It should avoid wording that presents research literature as product instructions or product claims.
For example, a model-specific paper associated with condition-related terminology should be described as a literature category only [27]. It should not be used to position Prostamax as a health product.
Search intent can drift when commercial keywords are mixed with consumer outcomes. The safe correction is to bring the page back to documentation.
Instead of answering consumer-facing intent, this page answers research procurement intent: COA, purity, identity, HPLC, LC-MS, lot number, label consistency, and RUO notice.
A COA is most useful when it is batch-specific, method-aware, and connected to the exact product listing. Certificates of analysis should not be treated as interchangeable across lots.
NIST describes reference materials as coming with documentation that states certified or reference values and related information [20]. That principle supports COA discipline for research materials.
A Prostamax COA should show the compound name, lot number, test date, testing method, purity result, identity support, and laboratory source. Where applicable, it should also show chromatographic or mass data.
A COA does not replace full analytical review. It is one document in a larger supplier documentation set.
COA dates and lot numbers should align with the product record being evaluated. If a COA points to a different lot, it should not be assumed to represent the listed material.
Batch matching is a documentation issue. It is not a scientific claim, but it is essential for technical procurement.
Third-party testing records can add confidence when the testing source, method, and lot connection are clear. ISO/IEC 17025 is a recognized framework for laboratory competence and valid results [21].
That does not mean every COA is equivalent. Research buyers should look for method details, identity support, and traceability.
HPLC and LC-MS serve different roles in peptide documentation. HPLC is commonly used to evaluate peptide purity and separation profiles, while LC-MS can support identity and impurity characterization [16] [17].
For research procurement, the practical question is whether the analytical method matches the claim being made. Purity and identity are related, but not identical.
HPLC supports peptide purity review by separating peptide-related components and producing chromatographic data that can be interpreted for purity assessment [16]. The chromatogram should connect to the relevant lot.
A purity percentage should be read with method context. Researchers should ask what method was used, what wavelength or detection system was applied, and whether the COA ties to the listed batch.
LC-MS supports identity review by connecting chromatographic separation with mass information. Synthetic peptide characterization literature describes LC-MS workflows for identifying impurities and confirming structural features in peptide analysis [17].
Peptide mapping literature also shows how LC-MS can connect mass data and sequence-related confirmation in analytical workflows [18]. For Prostamax, LC-MS documentation should align with KEDP identity information from PubChem [1].
Lot traceability links the product listing to the physical batch, COA, analytical record, and storage documentation. Without that link, product-page claims become difficult to audit.
A strong documentation set should allow a research team to follow the record from listing to batch to testing.
Each batch record should connect the compound name, lot number, COA, analytical method, test date, and storage notation. If any of these pieces are missing, the documentation review is incomplete.
Batch-specific documentation matters because peptide materials can vary by lot, test method, and storage history.
Label consistency means the same compound name, sequence, catalog amount, lot number, and RUO statement appear across documents. A listing such as Prostamax 20mg should be read as a catalog specification only.
The label should also avoid claims that conflict with the RUO frame. Product-page copy should stay consistent with research-use-only positioning.
Supplier documentation review is the practical core of commercial research intent. Researchers are not just comparing lab peptides by name; they are comparing the strength of the supporting record.
A useful supplier record should include product identity, COA availability, analytical data, lot traceability, storage notes, and RUO labeling.
Research buyers should compare COA availability, batch-level testing, analytical method clarity, label consistency, and documentation completeness. Supplier comparison should not rely on marketing language.
A source-quality filter helps: official database first, peer-reviewed literature second, analytical records third, marketing language last.
Quality standards support procurement review by giving teams a common vocabulary for laboratory competence, method validation, and documentation control. ICH Q2(R2) describes analytical procedure validation concepts such as suitability for intended analytical purpose [14].
FDA analytical-method guidance also discusses validation characteristics and method suitability for analytical procedures [15]. These sources are not product endorsements; they are documentation benchmarks.
Lyophilized peptide documentation should describe storage expectations in research-record terms. Storage conditions affect whether the material’s analytical record remains meaningful over time.
Peptide storage literature shows that peptide stability can vary by storage condition and peptide properties [24]. Documentation should therefore be specific rather than generic.
Lyophilized materials need storage notes because moisture, temperature, and handling history can affect peptide stability. Recommendations for peptide reference materials in quantitative workflows emphasize storage, stability, and documentation as part of analytical reliability [25].
For product pages, storage copy should support laboratory recordkeeping. It should not become preparation guidance.
Storage conditions should be documented as part of the laboratory record: date received, lot number, storage temperature, and any supplier storage notation. These details help preserve traceability.
The storage note should match the product label and COA when applicable. If the label and documentation disagree, the discrepancy should be resolved before research planning.
Several misunderstandings can weaken RUO product-page interpretation. The most common issue is treating literature as if it describes a product claim.
A second misunderstanding is treating a single purity percentage as complete identity confirmation. A third is treating catalog size as research interpretation.
A COA can support documentation review, but it does not prove every analytical question. HPLC purity data and LC-MS identity data answer different questions [16] [17].
A strong review asks whether the COA is batch-specific, whether the method is named, and whether identity evidence aligns with the expected compound.
Boundary-sensitive search terms should not become product claims. Terms tied to prostate health, condition-specific literature, or histology language such as infiltration require careful context.
The safer approach is to frame these terms as literature or claim-boundary issues. Product-page copy should return to COA, identity, purity, lot traceability, and RUO labeling.
Researchers avoid consumer-language drift by separating three layers: what the literature examined, what the COA documents, and what the product page may say. Those layers should not collapse into one claim.
For Prostamax research, the page should stay focused on peptide identity, published literature context, analytical verification, and documentation review.
The final review should ask one question: does the documentation support the research material listing? If the answer is unclear, the procurement record is not complete.
A strong record includes identity, purity, lot traceability, analytical testing, label consistency, storage documentation, and RUO positioning.
Review the product-page documentation, COA details, analytical testing information, lot traceability, and RUO labeling before evaluating Prostamax for laboratory research. For research teams comparing peptide suppliers, prioritize transparent documentation over marketing language.
Research use only means Prostamax is intended solely for laboratory research contexts. Product-page evaluation should focus on RUO labeling, compound characterization, COA review, batch-specific documentation, and supplier records. Products are for research use only and are not intended for human or animal consumption.
Researchers should consider documentation before they buy Prostamax for research. A research procurement review should check the product listing, COA, lot traceability, peptide identity, storage documentation, and analytical testing records. Catalog details should be treated as listing information, not as instructions or outcome-based positioning.
A COA matters because it helps connect Prostamax documentation to a specific lot, test date, purity review, and identity record. Research buyers should review whether the COA aligns with the product label and batch-specific documentation. A COA is strongest when paired with clear supplier documentation and method details.
Published literature about Prostamax should be interpreted as research context, not product-use guidance. Literature discussing peptide bioregulation, tissue-specific models, or chromatin-related research should remain separate from product claims. Model-specific findings can guide source review, but they should not be converted into claims about a research material.
Chromatin model terms help describe the research literature around Prostamax without turning that literature into product positioning. Phrases such as heterochromatin of human lymphocytes, human lymphocytes in situ, and frequency of sister chromatid exchanges should be framed as literature-context terms. They belong in research interpretation, not claim language.
Prostamax product-page evaluation is supported by RUO labeling, COA availability, compound characterization, lot traceability, storage documentation, and rigorous testing records. Cell culture research or other model references should be interpreted alongside documentation quality. The most useful product page keeps research purposes, analytical review, and claim boundaries clearly separated.
The following authors are recognized for published research that helped shape the scientific context discussed in this article.
Author profile: PubMed Author Search
Vladimir Khavinson is a published research author whose work is frequently associated with short peptide literature, peptide bioregulation, chromatin context, and gene-expression models. His publications provide useful background for interpreting Prostamax within a research-use-only product page because they discuss short peptides as molecular research subjects rather than consumer-facing materials. The selected publications below are relevant to the article’s discussion of bioregulator peptide research, compound context, and literature interpretation.
Selected publications:
Author profile: PubMed Author Search
Teimuraz Lezhava is a research author whose publications are directly relevant to the chromatin and lymphocyte model literature discussed in this article. His co-authored work appears in studies connected to Prostamax, heterochromatin, and short peptide research models, offering useful context for how laboratory findings should be interpreted on an RUO product page. These publications support the article’s emphasis on model-specific literature, careful research framing, and separation between published research and product-page claims.
Selected publications:
This research disclaimer clarifies how this page handles published literature and search language around Prostamax. In Bioregulator Peptide Research content, terms such as sclerotic and atrophic, lymphoid infiltration, chronic inflammation, benign prostatic hyperplasia, men’s prostate health, and peptide therapy can drift into consumer-facing, wellness, clinical-use, therapeutic, or product-claim language when framed incorrectly.
Here, those phrases are handled only as research-language examples, not as product positioning, outcomes, instructions, or recommendations. The same care applies to product effects, wellness language, clinical outcomes, therapeutic language, and administration-focused language, which should remain separate from Prostamax identity, COA review, analytical testing, peptide purity, lot traceability, RUO labeling, product documentation, and published literature boundaries.
Our team is ready to assist you with any inquiries regarding our catalogue of peptides and their applications.
Discount Applied Successfully!
Your savings have been added to the cart.
There are no reviews yet.